45
Participants
Start Date
September 30, 2008
Primary Completion Date
April 30, 2010
Study Completion Date
July 31, 2010
Placebo
Dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
Maraviroc
Dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
Case Western Reserve University, Cleveland
Rush University - Stroger Hospital of Cook County, Chicago
University of California San Francisco - San Francisco General Hospital, San Francisco
Stanford University, Stanford
Collaborators (1)
Pfizer
INDUSTRY
amfAR, The Foundation for AIDS Research
OTHER
Stanford University
OTHER
Case Western Reserve University
OTHER
Rush University
OTHER
University of California, San Francisco
OTHER